JRCT ID: jRCT2080225261
Registered date:03/07/2020
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 03/07/2020 |
Target sample size | 400 |
Countries of recruitment | Japan,Asia except Japan,North America,South America,Europe,null |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : Baricitinib Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : --- Other Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | efficacy |
---|---|
Secondary Outcome | efficacy |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | Eli Lilly Japan K.K. |
---|---|
Secondary Sponsor | - |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT04421027,JapicCTI-205357 |